Will Microbot Medical's Robotic Surgery System Be a Big Hit?
Microbot Medical Inc. (NASDAQ: MBOT) shares made a massive gain on Tuesday after the company revealed its Liberty system, which would be the world’s first fully disposable robotic system for use in neurovascular, cardiovascular and peripheral vascular procedures.
The Liberty robotic system is said to have the capability to be operated remotely, reduce radiation exposure and physical strain to the physician, as well as the potential to eliminate the use of multiple consumables through its “One & Done” capabilities.
Microbot is set to publicly display and demonstrate its Liberty system to investors, journalists and health care industry leaders on Monday, January 13, 2020, in San Francisco.
Harel Gadot, CEO, president and board chair, commented:
Liberty is set to revolutionize the way surgical robotics are being used in endovascular procedures, by eliminating the need for capital equipment, reducing radiation exposure and aiming to streamline the use of disposables during these complex procedures. In addition, with Liberty’s remote operation as well as its “One & Done” capabilities, we believe it has the potential to be the first system to democratize endovascular interventional procedures.
Excluding Tuesday’s move, Microbot had outperformed the broad markets, with its stock up about 488% year to date. In the past six months, the stock was up 106%.
Shares of Microbot Medical were last seen up about 60% at $16.23, in a 52-week range of $1.48 to $19.40. The consensus price target is $10.00